Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 19;16(16):2535-2545.
doi: 10.1002/cmdc.202100210. Epub 2021 May 24.

A Structure-Activity Relationship Study of Bimodal BODIPY-Labeled PSMA-Targeting Bioconjugates

Affiliations

A Structure-Activity Relationship Study of Bimodal BODIPY-Labeled PSMA-Targeting Bioconjugates

Tobias Stemler et al. ChemMedChem. .

Abstract

The aim of this study was to identify a high-affinity BODIPY peptidomimetic that targets the prostate-specific membrane antigen (PSMA) as a potential bimodal imaging probe for prostate cancer. For the structure-activity study, several BODIPY (difluoroboron dipyrromethene) derivatives with varying spacers between the BODIPY dye and the PSMA Glu-CO-Lys binding motif were prepared. Corresponding affinities were determined by competitive binding assays in PSMA-positive LNCaP cells. One compound was identified with comparable affinity (IC50 =21.5±0.1 nM) to Glu-CO-Lys-Ahx-HBED-CC (PSMA-11) (IC50 =18.4±0.2 nM). Radiolabeling was achieved by Lewis-acid-mediated 19 F/18 F exchange in moderate molar activities (∼0.7 MBq nmol-1 ) and high radiochemical purities (>99 %) with mean radiochemical yields of 20-30 %. Cell internalization of the 18 F-labeled high-affinity conjugate was demonstrated in LNCaP cells showing gradual increasing PSMA-mediated internalization over time. By fluorescence microscopy, localization of the high-affinity BODIPY-PSMA conjugate was found in the cell membrane at early time points and also in subcellular compartments at later time points. In summary, a high-affinity BODIPY-PSMA conjugate has been identified as a suitable candidate for the development of PSMA-specific dual-imaging agents.

Keywords: BODIPY; PET; PSMA; bimodal imaging; fluorescence imaging.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1
Scheme 1
A) difluoroboron dipyrromethene (BODIPY) scaffold. B) BODIPY dyes 1 with a carboxylic acid functionality for bioconjugation and its corresponding NHS ester 2 used in this study.
Scheme 2
Scheme 2
Synthetic procedure for the preparation of BODIPY‐PSMA bioconjugates 3–6 using a combination of solid‐phase and solution‐based chemistry.
Figure 1
Figure 1
ORTEP representation of 2 with thermal ellipsoids drawn at 50 % probability level.
Figure 2
Figure 2
Normalized A) absorption and B) emission spectra (λexc=460 nm) of 1 in 95 % TFA at different time points. Normalized C) absorption and D) emission spectra (λexc=460 nm) of 1 in 1 M SnCl4 in acetonitrile at different time points.
Scheme 3
Scheme 3
Representative radiolabeling of BODIPY‐PSMA conjugate 4 by Lewis acid mediated isotopic 19F/18F exchange.
Figure 3
Figure 3
A) Representative UV/vis HPLC chromatogram of 4 (insert: MS spectrum of 4). B) Radio‐HPLC chromatogram of [18F]F‐4. C) Representative UV/vis HPLC chromatogram of 4 without BF2 (insert: MS spectrum of 4 ‐BF2). D) UV/vis HPLC chromatogram of [18F]F‐4 showing loss of the BF2 entity during radiolabeling by Lewis acid mediated isotopic 19F/18F isotopic exchange.
Figure 4
Figure 4
PSMA‐specific surface bound and internalized fractions of [18F]F‐4 in LNCaP cells. Values are given as mean±SD. Results are from two independent experiments in triplicate.
Figure 5
Figure 5
PSMA‐mediated uptake of 4 into LNCaP cells, confirmed by SIM‐fluorescence microscopy over time at 25 °C at A) 15 min, B) 30 min, C) 1 h, D) 1 h at 4 °C, E) 1 h+2‐PMPA, F) DAPI control.

Similar articles

Cited by

References

    1. Kosaka N., Ogawa M., Choyke P. L., Kobayashi H., Future Oncol. 2009, 5, 1501–1511. - PMC - PubMed
    1. Bu L., Shen B., Cheng Z., Adv. Drug Delivery Rev. 2014, 76, 21–38. - PMC - PubMed
    1. Tipirneni K. E., Rosenthal E. L., Moore L. S., Haskins A. D., Udayakumar N., Jani A. H., Carroll W. R., Morlandt A. B., Bogyo M., Rao J., Warram J. M., Mol. Imaging Biol. 2017, 19, 645–655. - PubMed
    1. Kowada T., Maeda H., Kikuchi K., Chem. Soc. Rev. 2015, 44, 4953–4972. - PubMed
    1. Ntziachristos V., Bremer C., Weissleder R., Eur. Radiol. 2003, 13, 195–208. - PubMed

Publication types

MeSH terms